Metabolic-Associated Fatty Liver Disease and Cognitive Performance in Type 2 Diabetes: Basal Data from the Phytate, Neurodegeneration and Diabetes (PHYND) Study
Antelm Pujol,
Pilar Sanchis,
María I. Tamayo,
Samantha Godoy,
Paula Calvó,
Asier Olmos,
Pilar Andrés,
Aleksandra Speranskaya,
Ana Espino,
Ana Estremera,
Elena Rigo,
Guillermo J. Amengual,
Manuel Rodríguez,
José Luis Ribes,
Isabel Gomila,
Félix Grases,
Marta González-Freire,
Lluís Masmiquel
Affiliations
Antelm Pujol
Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
Pilar Sanchis
Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
María I. Tamayo
Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
Samantha Godoy
Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
Paula Calvó
Laboratory of Renal Lithiasis Research, University of Balearic Islands, Research Institute of Heath Science (IUNICS), Health Research Institute of Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
Asier Olmos
Neuropsychology and Cognition, Department of Psychology, Research Institute of Heath Science (IUNICS), University of Balearic Islands, Health Research Institute of Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
Pilar Andrés
Neuropsychology and Cognition, Department of Psychology, Research Institute of Heath Science (IUNICS), University of Balearic Islands, Health Research Institute of Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
Aleksandra Speranskaya
Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
Ana Espino
Neurology Department, Son Llàtzer University Hospital, 07198 Palma de Mallorca, Spain
Ana Estremera
Neuroradiology Department, Son Llàtzer University Hospital, 07198 Palma de Mallorca, Spain
Elena Rigo
Balearic Research Group on Genetic Cardiopathies, Sudden Death, and TTR Amyloidosis, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
Guillermo J. Amengual
Neuroradiology Department, Son Llàtzer University Hospital, 07198 Palma de Mallorca, Spain
Manuel Rodríguez
Neuroradiology Department, Son Llàtzer University Hospital, 07198 Palma de Mallorca, Spain
José Luis Ribes
Clinical Analysis Department, Son Llàtzer University Hospital, 07198 Palma de Mallorca, Spain
Isabel Gomila
Clinical Analysis Department, Son Llàtzer University Hospital, 07198 Palma de Mallorca, Spain
Félix Grases
Laboratory of Renal Lithiasis Research, University of Balearic Islands, Research Institute of Heath Science (IUNICS), Health Research Institute of Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
Marta González-Freire
Translational Research in Aging and Longevity (TRIAL) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
Lluís Masmiquel
Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
The effect of liver fibrosis on mild cognitive impairment (MCI) and dementia risk in type 2 diabetes mellitus (T2DM) patients is unclear. Therefore, we performed a prospective cross-sectional study on 219 patients with T2DM and older than 60 years to evaluate the association between liver fibrosis, liver steatosis, and cognitive impairment. The Montreal Cognitive Assessment (MoCA) was used to screen for MCI or dementia. Liver fibrosis was estimated using the non-invasive Fibrosis-4 (FIB-4) score, and liver steatosis was assessed with the hepatic steatosis index. The mean age was 71 ± 6 years, 47% were women and according to MoCA cut-off values, 53.88% had MCI and 16.43% had dementia. A moderate or high risk of advanced fibrosis was significantly higher in patients with MCI or dementia compared to those with normal cognition (p p = 0.039). Multivariate analysis identified age over 70.5 years, antiplatelet medication use, and a FIB-4 score above 1.54 as the most relevant risk factors. Liver fibrosis, but not liver steatosis, is associated with MCI or dementia in older T2DM patients, suggesting that FIB-4 score might be a simple biomarker for the detection of cognitive impairment.
